Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Cancer Type/Condition:  Brain tumor, child: Ependymoma/Ependymal tumors
Trial Type:  Treatment
Trial Status:  Active
Results 1-25 of 34 for your search:
Start Over
An International Clinical Program for the Diagnosis and Treatment of Children With Ependymoma
Phase: Phase III, Phase II
Type: Treatment
Status: Approved-not yet active
Age: 22 and under
Sponsor: Other
Protocol IDs: SIOP Ependymoma II (ET-13-002), 2013-002766-39, VHP358, NCT02265770
Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Younger Patients With Newly Diagnosed Ependymoma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 1 to 21
Sponsor: NCI, Other
Protocol IDs: ACNS0831, NCI-2011-02029, COG-ACNS0831, CDR0000668560, U10CA098543, NCT01096368
Study of Fixed vs. Flexible Filgrastim to Accelerate Bone Marrow Recovery After Chemotherapy in Children With Cancer
Phase: Phase III
Type: Treatment
Status: Active
Age: 1 to 25
Sponsor: NCI, Other
Protocol IDs: 2013-062, NCI-2013-02001, P30CA022453, NCT01987596
Crizotinib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 1 to 21
Sponsor: NCI, Other
Protocol IDs: ADVL0912, COG-ADVL0912, CDR0000647587, NCT00939770
Clinical Study of Vorinostat in Combination With Etoposide in Pediatric Patients < 21 Years at Diagnosis With Refractory Solid Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 4 to 21
Sponsor: Other
Protocol IDs: 10-096, NCT01294670
Safety and Efficacy of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 2 to 18
Sponsor: Pharmaceutical / Industry
Protocol IDs: TED12689, U1111-1128-5704, NCT01751308
Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Any age
Sponsor: Other
Protocol IDs: 05-122, MSKCC-05122, NCT00445965
High-dose Chemotherapy With Autologous Stem Cell Rescue in Pediatric High-risk Brain Tumors
Phase: Phase II
Type: Treatment
Status: Active
Age: Children
Sponsor: Other
Protocol IDs: 2005-12-009, NCT00798811
Antineoplaston Therapy in Treating Children With Brain Tumors
Phase: Phase II
Type: Treatment
Status: Active
Age: 6 months to 17 years
Sponsor: Other
Protocol IDs: CDR0000066490, BC-BT-10, NCT00003458
Antineoplaston Therapy in Treating Children With Primary Malignant Brain Tumors
Phase: Phase II
Type: Treatment
Status: Active
Age: 6 months to 17 years
Sponsor: Other
Protocol IDs: CDR0000066513, BC-BT-22, NCT00003476
Proton Radiotherapy for Pediatric Brain Tumors Requiring Partial Brain Irradiation
Phase: Phase II
Type: Natural history/Epidemiology, Treatment
Status: Active
Age: 1 to 25
Sponsor: NCI, Other
Protocol IDs: 10-206, NCT01288235
Tandem High Dose Chemotherapy and Autologous Stem Cell Rescue for High Risk Pediatric Brain Tumors
Phase: Phase II
Type: Treatment
Status: Active
Age: 21 and under
Sponsor: Other
Protocol IDs: SNUCH-SCT-1102, NCT01342237
A Trial of Surgery and Fractionated Re-Irradiation for Recurrent Ependymoma
Phase: Phase II
Type: Treatment
Status: Active
Age: 1 to 21
Sponsor: Other
Protocol IDs: RERTEP, NCI-2014-00906, NCT02125786
Everolimus for Children With Recurrent or Progressive Ependymoma
Phase: Phase II
Type: Treatment
Status: Active
Age: 2 to 21
Sponsor: Other
Protocol IDs: CRAD001CUS224T, NCT02155920
Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors
Phase: Phase I
Type: Treatment
Status: Active
Age: 2 to 25
Sponsor: NCI, Other
Protocol IDs: CDR0000257582, UIHC-200008086, NCI-V02-1710, 200008086, NCT00049023
A Trial of Everolimus and Bevacizumab in Children With Recurrent Solid Tumors
Phase: Phase I
Type: Treatment
Status: Active
Age: 21 and under
Sponsor: Other
Protocol IDs: RADBEV, NCI-2011-01149, NCT00756340
Study of Busulfan for Refractory Central Nervous System (CNS) Tumors
Phase: Phase I
Type: Treatment
Status: Approved-not yet active
Age: 3 to 21
Sponsor: Other
Protocol IDs: CNS 1100, NCT00836628
A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors
Phase: Phase I
Type: Treatment
Status: Active
Age: 3 to 22
Sponsor: Pharmaceutical / Industry
Protocol IDs: 07-098, NCT00634231
Lenalidomide and Radiation Therapy in Treating Young Patients With Pontine Glioma or High-Grade Glioma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Under 19 at diagnosis
Sponsor: NCI
Protocol IDs: NCI-2011-02539, 10-C-0219, CDR0000687467, NCI-10-C-0219, 8449, NCT01226940
Photodynamic Therapy (PDT) for Brain Tumors
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and under
Sponsor: Other
Protocol IDs: 163588-1, NCT01682746
Dendritic Cell Vaccine For Malignant Glioma and Glioblastoma Multiforme in Adult and Pediatric Subjects
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 13 to 99
Sponsor: Other
Protocol IDs: 20120750, NCT01808820
Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 4 to 21
Sponsor: NCI, Other
Protocol IDs: PBTC-042, U01CA081457, NCT02255461
Fourth Ventricle Infusions of Autologous Ex Vivo Expanded NK Cells in Children With Recurrent Posterior Fossa Tumors
Phase: Phase I
Type: Treatment
Status: Active
Age: 21 and under
Sponsor: Other
Protocol IDs: 2013-0765, NCI-2014-02677, NCT02271711
Phase I Trial of Afatinib in Pediatric Tumours
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 2 to 17
Sponsor: Pharmaceutical / Industry
Protocol IDs: 1200.120, 2014-002123-10, NCT02372006
Pomalidomide in Treating Younger Patients With Recurrent, Progressive or Refractory Central Nervous System Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: 3 to 20
Sponsor: NCI
Protocol IDs: NCI-2014-02182, PBTC-043, UM1CA081457, NCT02415153
Start Over